CoaguChek®: The Point of Care coagulation monitoring solution from Roche

Your trusted companion for anticoagulation care from the hospital to patients' homes.


Coagulation self-testing can reduce visits to the clinic and improve time in the therapeutic range1-5

Since 1992, CoaguChek® by Roche Diagnostics, has led the way in Point of Care (POC) testing, developing innovative solutions in coagulation monitoring for both professionals and patients alike. As a market leader in POC International Normalised Ratio (INR) monitoring solutions, CoaguChek®, has played a vital role in anticoagulation therapy, particularly for patients on Vitamin K Antagonist (VKA) medications such as warfarin.

Patient Self Testing of INR has emerged as a resounding success story. Patients managed with POC testing achieve a higher time in therapeutic range and fewer values out of range compared with patients treated with usual care.1-3 This results in fewer treatment-related complications,4,5 fewer hospitalisations and accident and emergency visits,4,5 and improved patient satisfaction.6-8

Despite the advent of Direct Oral Anticoagulants (DOACs), which have become the preferred choice for many patients, there remains a crucial segment for whom DOACs are not suitable. For these patients, CoaguChek® continues to be the cost-effective and proven INR monitoring solution, ensuring reliable and personalised care.

An HCP is sitting in a clinic setting with a patient. Together they are observing the data on a CoaguChek INRange system.

CoaguChek® solutions for the Point of Care

Performed by healthcare professionals immediately at the patient's point of care. CoaguChek® offers reliable and easy-to-use solutions that provide immediate results, allowing treatment decisions to be made promptly.

Featured products

CoaguChek INRange is the connected self-testing meter that enables your patients to test their PT/INR whenever, wherever - for confident control of their VKA therapy.
The CoaguChek® Pro II is an in vitro diagnostic instrument intended for the determination of PT and aPTT in whole blood using the CoaguChek PT Test and CoaguChek aPTT Test. The CoaguChek® Pro II is intended for near-patient testing. Not for self-testing.Released and launched parameters are country‑specific. Only parameters available on the market in the respective country can be activated.

Contact us

Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

References

  1. Harrison et al. (2015). Int J Pharm Pract. 23, 173-181.
  2. Okuyama et al. (2014). Circ J. 78, 1342-1348.
  3. Mearns et al. (2014). Thromb J., 12:14.
  4. Karlsson. (2016). BMJ Qual Improv Rep. 5, pii.w4421.
  5. Kong et al. (2008). Ann Hematol. 87, 905-910.
  6. Chan et al. (2006). Br J Clin Pharmacol. 62, 601-609.
  7. Thompson et al. (2009). Pharm Pract (Granada) 7, 213-217.
  8. Wurster & Doran. (2006). Dis Manag. 9, 201-209.